[CAS NO. 60-32-2] 6-Aminocaproicacid
PRODUCTS SPECIFICATIONS [60-32-2]
DESCRIPTION [60-32-2]
Overview
| MDL | MFCD00008238 |
|---|---|
| Molecular Weight | 131.17 |
| Molecular Formula | C6H13NO2 |
| SMILES | O=C(O)CCCCCN |
Summary
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen . 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders [1] [2] .
In Vitro
6-Aminocaproic acid (20-180 μg/mL) inhibits fibrinolysis in plasma of Asian elephants, with an effective concentration of 61.5 μg/mL
[2]
.
6-Aminocaproic acid can be used as a hydrophobic linker to improve near-infrared fluorescence imaging and photothermal cancer therapy of PEGylated indocyanine green
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
6-Aminocaproic acid (20-100 mg/kg; a single p.o.) inhibits fibrinolysis at all doses tested in dogs
[3]
.
6-Aminocaproic acid (20-100 mg/kg; a single p.o.) is rapidly absorbed (T
max
=1 h) and eliminated rapidly in dogs
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01965730 | University of Pennsylvania |
Aortic Disease
|
January 2013 | Early Phase 1 |
| NCT01391182 | Mayo Clinic |
Degenerative Joint Disease|Osteoarthritis
|
July 2011 | Not Applicable |
| NCT02074436 | Emory University |
Hematological Malignancies|Thrombocytopenia
|
May 23, 2014 | Phase 2 |
| NCT01873768 | Miller Orthopedic Specialists|CHI Health Mercy Hospital|Creighton University Medical Center |
Osteoarthritis
|
January 2014 | Phase 4 |
| NCT05291312 | Assiut University |
Adenoid Hypertrophy
|
May 1, 2022 | Not Applicable |
| NCT00320619 | National Heart, Lung, and Blood Institute (NHLBI) |
Scoliosis|Kyphosis|Lordosis|Spondylitis|Spinal Stenosis
|
September 2000 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : ≥ 50 mg/mL ( 381.18 mM )
DMSO : 1 mg/mL ( 7.62 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (190.59 mM); Clear solution; Need ultrasonic
References
- [1] Griffin JD, et, al. Epsilon-aminocaproic acid (EACA). Semin Thromb Hemost. Summer 1978;5(1):27-40.
- [2] Kaye S, et, al. EFFECT OF ε-AMINOCAPROIC ACID ON FIBRINOLYSIS IN PLASMA OF ASIAN ELEPHANTS (ELEPHAS MAXIMUS). J Zoo Wildl Med. 2016 Jun;47(2):397-404.
- [3] Brown JC, et, al. Effect of aminocaproic acid on clot strength and clot lysis of canine blood determined by use of an in vitro model of hyperfibrinolysis. Am J Vet Res. 2016 Nov;77(11):1258-1265.
- [4] Hu Q, et al. 6-Aminocaproic acid as a linker to improve near-infrared fluorescence imaging and photothermal cancer therapy of PEGylated indocyanine green. Colloids Surf B Biointerfaces. 2021 Jan;197:111372.
Synonyms